<DOC>
	<DOCNO>NCT00744640</DOCNO>
	<brief_summary>Gemcitabine mainstay palliative chemotherapy patient advance pancreatic cancer ( APC ) . Recent randomized trial show increased clinical benefit addition oxaliplatin prolong median survival addition capecitabine gemcitabine . Gemcitabine , capecitabine oxaliplatin 3 newer , well tolerated anticancer drug mild non-overlapping toxicity profile . We therefore propose dose-finding safety study triple combination gemcitabine , capecitabine oxaliplatin patient APC ( Phase I part ) , follow phase II part ass preliminary efficacy triple combination .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin Capecitabine Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description>Primary Objectives : - Phase I : determine maximum tolerate dose ( MTD ) oxaliplatin combination gemcitabine capecitabine ( GEMOXEL ) patient APC - Phase II : assess anti-tumor activity GEMOXEL patient APC Secondary Objectives : - ass toxicity safety combination treatment GEMOXEL patient APC Primary Endpoints : - Phase I : Dose-limiting toxicity - Phase II : Objective tumor response Secondary Endpoints : - Toxicity MTD accord NCI CTC 3.0 - Progression-free survival Overall Survival</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Cytologically histologically confirm adenocarcinoma exocrine pancreas Disease nonresectable locally advanced metastatic Measurable disease evaluable disease i.e . tumor marker CA199 baseline ≥ 1.5 x upper limit normal ( ULN ) Age &gt; 18 year Karnofsky performance status ≥ 60 % Life expectancy least 3 month Written inform consent Willing able comply protocol duration study Prior chemotherapy pancreatic cancer Prior adjuvant radio radiochemotherapy pancreatic cancer within 12 month inclusion Known CNS metastases time enrollment Neutrophil count ≤ 1.5 x109/l , platelet count ≤100 x109/l , hemoglobin ≤ 10g/dl Serum creatinine &gt; 1.25 x ULN ASAT , ALAT alkaline phosphatase &gt; 2.5 ULN &gt; 5 ULN presence liver metastasis , Bilirubin &gt; 1.5 ULN ( treatment obstructive jaundice eg . stent ) Pregnant breast feed woman ( woman childbearing potential must negative pregnancy test baseline ) Men woman reproductive potential use effective method contraception Clinically significant cardiac disease ( NYHA IIIIV ) myocardial infarction within last 12 month Neurological disease dys/paraesthesias &gt; grade 1 accord NCI CTC Any serious concomitant disorder incompatible trial ( judgement investigator ) Psychiatric disability think clinically significant opinion investigator preclude informed consent interfere compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>palliative chemotherapy</keyword>
	<keyword>first-line therapy</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>dose-finding study</keyword>
	<keyword>Phase II</keyword>
</DOC>